G. Dranoff, Cytokines in cancer pathogenesis and cancer therapy, Nat Rev Cancer, vol.4, pp.11-22, 2004.

M. B. Brenner, J. Mclean, D. P. Dialynas, J. L. Strominger, J. A. Smith et al., Identification of a putative second T-cell receptor, Nature, vol.322, pp.145-154, 1986.

H. Saito, D. M. Kranz, Y. Takagaki, A. C. Hayday, H. N. Eisen et al., Complete primary structure of a heterodimeric T-cell receptor deduced from cDNA sequences, Nature, vol.309, pp.757-62, 1984.

A. R. Kazen and E. J. Adams, Evolution of the VD and J gene segments used in the primate ? ? T-cell receptor reveals a dichotomy of conservation and diversity, Proc Natl Acad Sci, vol.108, pp.332-372, 2011.

E. Sturm, R. E. Bontrop, R. J. Vreugdenhil, N. Otting, and R. L. Bolhuis, Tcell receptor gamma/delta: comparison of gene configurations and function between humans and chimpanzees, Immunogenetics, vol.36, pp.294-301, 1992.

Y. Zhao, C. Niu, and J. Cui, Gamma-delta (??) T cells: friend or foe in cancer development?, J Transl Med, vol.16, p.3, 2018.

M. P. Lefranc and T. H. Rabbitts, Evolution and function of the TCR Vgamma9 chain repertoire: it's good to be public, Cell Immunol, vol.141, pp.22-30, 1990.

P. Vantourout and A. Hayday, Six-of-the-best: unique contributions of ?? T cells to immunology, Nat Rev Immunol, vol.13, pp.88-100, 2013.

M. Rigau, S. Ostrouska, T. S. Fulford, D. N. Johnson, K. Woods et al., Butyrophilin 2A1 is essential for phosphoantigen reactivity by ?? T cells, Science, vol.367, p.5516, 2020.

M. M. Karunakaran, C. R. Willcox, M. Salim, D. Paletta, A. S. Fichtner et al., Butyrophilin-2A1 directly binds germline-encoded regions of the V?9V?2 TCR and is essential for phosphoantigen sensing, Immunity, vol.52, pp.487-98, 2020.

L. Boutin and E. Scotet, Towards deciphering the hidden mechanisms that contribute to the antigenic activation process of human V?9V?2 T cells, Front Immunol, vol.9, p.828, 2018.

I. Coppens, Targeting lipid biosynthesis and salvage in apicomplexan parasites for improved chemotherapies, Nat Rev Microbiol, vol.11, pp.823-858, 2013.

K. Thompson and M. J. Rogers, Statins prevent bisphosphonate-induced ? ,?-T-cell proliferation and activation in vitro, J Bone Miner Res Off J Am Soc Bone Miner Res, vol.19, pp.278-88, 2004.

S. T. Ribeiro, J. C. Ribot, and B. Silva-santos, Five layers of receptor signaling in ?? T-cell differentiation and activation, Front Immunol, vol.6, p.15, 2015.

T. Hoeres, M. Smetak, D. Pretscher, and M. Wilhelm, Improving the efficiency of V?9V?2 T-cell immunotherapy in cancer, Front Immunol, vol.9, p.800, 2018.

H. Gober, M. Kistowska, L. Angman, P. Jenö, L. Mori et al., Human T cell receptor ? ? cells recognize endogenous mevalonate metabolites in tumor cells, J Exp Med, vol.197, pp.163-171, 2003.

C. Harly, C. Peigné, and E. Scotet, Molecules and mechanisms implicated in the peculiar antigenic activation process of human V?9V?2 T cells, Front Immunol, vol.5, p.657, 2014.

B. Silva-santos, K. Serre, and H. Norell, ?? T cells in cancer, Nat Rev Immunol, vol.15, pp.683-91, 2015.

V. Kunzmann, E. Bauer, J. Feurle, F. Weissinger, H. P. Tony et al., Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma, Blood, vol.96, pp.384-92, 2000.

E. Sturm, E. Braakman, P. Fisch, R. J. Vreugdenhil, P. Sondel et al., Human V? 9-V?2 T cell receptor-gamma delta lymphocytes show specificity to Daudi Burkitt's lymphoma cells, J Immunol Baltim Md, vol.145, pp.3202-3210, 1990.

H. Kobayashi, Y. Tanaka, J. Yagi, H. Toma, and T. Uchiyama, Gamma/delta T cells provide innate immunity against renal cell carcinoma, Cancer Immunol Immunother CII, vol.50, pp.115-139, 2001.

E. Viey, G. Fromont, B. Escudier, Y. Morel, D. Rocha et al., Phosphostim-activated ? ? T cells kill autologous metastatic renal cell carcinoma, J Immunol Baltim Md, vol.174, pp.1338-1385, 1950.

M. Corvaisier, A. Moreau-aubry, E. Diez, J. Bennouna, J. Mosnier et al., V? 9V?2 T cell response to colon carcinoma cells, J Immunol Baltim Md, vol.175, pp.5481-5489, 1950.

M. R. Dunne, B. A. Mangan, L. Madrigal-estebas, and D. G. Doherty, Preferential Th1 cytokine profile of phosphoantigen-stimulated human V?9V?2 T cells, Mediators Inflamm, p.704941, 2010.

V. E. García, P. A. Sieling, J. Gong, P. F. Barnes, K. Uyemura et al., Single-cell cytokine analysis of gamma delta T cell responses to nonpeptide mycobacterial antigens, J Immunol Baltim Md, vol.159, pp.1328-1363, 1950.

M. Girardi, E. Glusac, R. B. Filler, S. J. Roberts, I. Propperova et al., The distinct contributions of murine T cell receptor (TCR)??+ and TCR??+ T cells to different stages of chemically induced skin cancer, J Exp Med, vol.198, pp.747-55, 2003.

D. Kabelitz, D. Wesch, E. Pitters, and M. Zöller, Characterization of tumor reactivity of human V? 9V?2? ? T cells in vitro and in SCID mice in vivo, J Immunol Baltim Md, vol.173, pp.6767-76, 1950.

B. J. Zheng, K. W. Chan, S. Im, D. Chua, J. S. Sham et al., Anti-tumor effects of human peripheral ? ? T cells in a mouse tumor model, Int J Cancer, vol.92, pp.421-426, 2001.

A. J. Gentles, A. M. Newman, C. L. Liu, S. V. Bratman, W. Feng et al., The prognostic landscape of genes and infiltrating immune cells across human cancers, Nat Med, vol.21, pp.938-983, 2015.

L. Presti, E. Dieli, F. Meraviglia, and S. , Tumor-infiltrating ?? T lymphocytes: pathogenic role, clinical significance, and differential programing in the tumor microenvironment, Front Immunol, vol.5, p.607, 2014.

J. Fournié, H. Sicard, M. Poupot, C. Bezombes, A. Blanc et al., What lessons can be learned from ?? T cell-based cancer immunotherapy trials?, Cell Mol Immunol, vol.10, pp.35-41, 2013.

Z. Sebestyen, I. Prinz, J. Déchanet-merville, B. Silva-santos, and J. Kuball, Translating gammadelta (??) T cells and their receptors into cancer cell therapies, Nat Rev Drug Discov, vol.19, pp.169-84, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02407109

V. Kunzmann, E. Bauer, and M. Wilhelm, ? /? T-cell stimulation by pamidronate, N Engl J Med, vol.340, pp.737-745, 1999.

M. Wilhelm, V. Kunzmann, S. Eckstein, P. Reimer, F. Weissinger et al., ? ? T cells for immune therapy of patients with lymphoid malignancies, Blood, vol.102, pp.200-206, 2003.

F. Dieli, N. Gebbia, F. Poccia, N. Caccamo, C. Montesano et al., Induction of ? ? T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo, Blood, vol.102, pp.2310-2311, 2003.

F. Dieli, D. Vermijlen, F. Fulfaro, N. Caccamo, S. Meraviglia et al., Targeting human ? ? T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer, Cancer Res, vol.67, pp.7450-7457, 2007.

J. M. Lang, M. R. Kaikobad, M. Wallace, M. J. Staab, D. L. Horvath et al., Pilot trial of interleukin-2 and zoledronic acid to augment ?? T cells as treatment for patients with refractory renal cell carcinoma, Cancer Immunol Immunother CII, vol.60, pp.1447-60, 2011.

S. Meraviglia, M. Eberl, D. Vermijlen, M. Todaro, S. Buccheri et al., In vivo manipulation of V? 9V?2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients, Clin Exp Immunol, vol.161, pp.290-297, 2010.

M. Wilhelm, M. Smetak, K. Schaefer-eckart, B. Kimmel, J. Birkmann et al., Successful adoptive transfer and in vivo expansion of haploidentical ?? T cells, J Transl Med, vol.12, p.45, 2014.

J. Bennouna, V. Levy, H. Sicard, H. Senellart, M. Audrain et al., Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a V? 9V?2 T lymphocyte agonist in patients with solid tumors, Cancer Immunol Immunother CII, vol.59, pp.1521-1551, 2010.

H. Sicard, S. Ingoure, B. Luciani, C. Serraz, J. Fournié et al., In vivo immunomanipulation of V? 9V?2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model, J Immunol Baltim Md, vol.175, pp.5471-80, 1950.

H. Kobayashi, Y. Tanaka, J. Yagi, Y. Osaka, H. Nakazawa et al., Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study, Cancer Immunol Immunother CII, vol.56, pp.469-76, 2007.

M. Alnaggar, Y. Xu, J. Li, J. He, J. Chen et al., Allogenic V?9V?2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma, J Immunother Cancer, vol.7, p.36, 2019.

J. P. Fisher, J. Heuijerjans, M. Yan, K. Gustafsson, and J. Anderson, ?? T cells for cancer immunotherapy: a systematic review of clinical trials, Oncoimmunology, vol.3, p.27572, 2014.

T. Straetemans, G. Kierkels, R. Doorn, K. Jansen, S. Heijhuurs et al., GMP-grade manufacturing of T cells engineered to express a defined ??TCR, Front Immunol, vol.9, p.1062, 2018.

T. Santolaria, M. Robard, A. Léger, V. Catros, M. Bonneville et al., Repeated systemic administrations of both aminobisphosphonates and human V?9V?2 T cells efficiently control tumor development in vivo, J Immunol Baltim Md, vol.191, 1950.

S. Perrin, Preclinical research: make mouse studies work, Nature, vol.507, pp.423-428, 2014.

A. K. Wege, Humanized mouse models for the preclinical assessment of cancer immunotherapy, BioDrugs Clin Immunother Biopharm Gene Ther, vol.32, pp.245-66, 2018.

U. Jarry, C. Chauvin, N. Joalland, A. Léger, S. Minault et al., Stereotaxic administrations of allogeneic human V?9V?2 T cells efficiently control the development of human glioblastoma brain tumors, Oncoimmunology, vol.5, p.1168554, 2016.

N. Joalland, C. Chauvin, L. Oliver, F. M. Vallette, C. Pecqueur et al., IL-21 increases the reactivity of allogeneic human V?9V?2 T cells against primary glioblastoma tumors, J Immunother Hagerstown Md 1997, vol.41, pp.224-255, 2018.

N. Joalland, L. Lafrance, T. Oullier, S. Marionneau-lambot, D. Loussouarn et al., Combined chemotherapy and allogeneic human V?9V?2 T lymphocyte-immunotherapies efficiently control the development of human epithelial ovarian cancer cells in vivo, Oncoimmunology, vol.8, p.1649971, 2019.

J. Jung, H. S. Seol, and S. Chang, The generation and application of patient-derived xenograft model for cancer research, Cancer Res Treat Off J Korean Cancer Assoc, vol.50, pp.1-10, 2018.

J. J. Morton, G. Bird, Y. Refaeli, and A. Jimeno, Humanized mouse xenograft models: narrowing the tumor-microenvironment gap, Cancer Res, vol.76, pp.6153-6161, 2016.

C. D. Pauza, M. Liou, T. Lahusen, L. Xiao, R. G. Lapidus et al., Gamma delta T cell therapy for cancer: it is good to be local, Front Immunol, vol.9, p.1305, 2018.

T. Yuasa, K. Sato, E. Ashihara, M. Takeuchi, S. Maita et al., Intravesical administration of ? ? T cells successfully prevents the growth of bladder cancer in the murine model, Cancer Immunol Immunother CII, vol.58, pp.493-502, 2009.

C. Chauvin, N. Joalland, J. Perroteau, U. Jarry, L. Lafrance et al., NKG2D controls natural reactivity of V?9V?2 T lymphocytes against mesenchymal glioblastoma cells, Clin Cancer Res Off J Am Assoc Cancer Res, vol.25, pp.7218-7246, 2019.

G. Chitadze, M. Lettau, S. Luecke, T. Wang, O. Janssen et al., NKG2D-and T-cell receptor-dependent lysis of malignant glioma cell lines by human ?? T cells: modulation by temozolomide and A disintegrin and metalloproteases 10 and 17 inhibitors, Oncoimmunology, vol.5, p.1093276, 2016.

M. Todaro, V. Orlando, G. Cicero, N. Caccamo, S. Meraviglia et al., Chemotherapy sensitizes colon cancer initiating cells to V?9V?2 T cell-mediated cytotoxicity, PLoS ONE, vol.8, p.65145, 2013.

J. T. Zoine, K. A. Knight, L. C. Fleischer, K. S. Sutton, K. C. Goldsmith et al., Ex vivo expanded patient-derived ?? T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model, Oncoimmunology, vol.8, p.1593804, 2019.

C. Rossi, P. Gravelle, E. Decaup, J. Bordenave, M. Poupot et al., Boosting ?? T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma, Oncoimmunology, vol.8, p.1554175, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02347205

A. Capietto, L. Martinet, and J. Fournié, Stimulated ?? T cells increase the in vivo efficacy of trastuzumab in HER-2+ breast cancer

M. Immunol-baltim, , vol.187, pp.1031-1039, 1950.

J. Gertner-dardenne, C. Bonnafous, C. Bezombes, A. Capietto, V. Scaglione et al., Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies, Blood, vol.113, pp.4875-84, 2009.
URL : https://hal.archives-ouvertes.fr/hal-02348974

R. De-bruin, J. P. Veluchamy, S. M. Lougheed, F. L. Schneiders, S. Lopez-lastra et al., A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of V?9V?2-T cells, Oncoimmunology, vol.7, p.1375641, 2017.

A. Benyamine, L. Roy, A. Mamessier, E. Gertner-dardenne, J. Castanier et al., BTN3A molecules considerably improve V?9V?2T cellsbased immunotherapy in acute myeloid leukemia, Oncoimmunology, vol.5, p.1146843, 2016.

A. Thedrez, C. Harly, A. Morice, S. Salot, M. Bonneville et al., IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V? 9V?2 T cells for adoptive immunotherapy, J Immunol Baltim Md, vol.182, pp.3423-3454, 1950.

L. Kouakanou, Y. Xu, C. Peters, J. He, Y. Wu et al., Vitamin C promotes the proliferation and effector functions of human ?? T cells, Cell Mol Immunol, vol.17, pp.462-73, 2019.